miR-584-5p is a New Potential Prognostic Biomarker in Head and Neck Squamous Cell Carcinoma.

Current computer-aided drug design Pub Date : 2024-07-11 DOI:10.2174/0115734099305382240704071258

Donghong Yang, Guanbin Huang, Haiwen Li, Jing Huang, Haiqing Luo, Hualin Chen

{"title":"miR-584-5p is a New Potential Prognostic Biomarker in Head and Neck Squamous Cell Carcinoma.","authors":"Donghong Yang, Guanbin Huang, Haiwen Li, Jing Huang, Haiqing Luo, Hualin Chen","doi":"10.2174/0115734099305382240704071258","DOIUrl":null,"url":null,"abstract":"Background: MicroRNA-584-5p (miR-584-5p) plays an important role in certain types of cancer. However, its precise role in head and neck squamous cell carcinoma (HNSC) remains unknown.Objective: Our aim was to investigate how miR-584-5p influences HNSC.Methods: The Cancer Genome Atlas (TCGA) provided samples for the study. We use statistical methods to evaluate the diagnostic value, the prognostic value, and the correlation with the clinical features of miR-584-5p. We analyze the target genes and the regulatory network of miR- 584-5p. Quantitative reverse transcriptase PCR (qRT-PCR) confirmed the expression of miR- 584-5p in HNSC cell lines.Results: MiR-584-5p expression of miR-584-5p varied significantly among different types of cancer. A notable correlation was observed between elevated miR-584-5p expression and gender (p < 0.001) and histological grade (p < 0.001). Furthermore, high levels of miR-584-5p were found to be associated with a decrease in overall survival (HR: 1.44; 95% CI: 1.10-1.88; p = 0.007), progression-free survival (HR: 1.35; 95% CI: 1.02-1.79; p = 0.035) and disease-specific survival (HR: 1.54; 95% CI: 1.09-2.18; p = 0.016) in the context of HNSC. miR-584-5p demonstrated independent prognostic significance in HNSC and potentially contributes to disease progression through multiple pathways, such as dilated cardiomyopathy and hypertrophic cardiomyopathy. In particular, HNSC cell lines exhibited a substantial upregulation of miR-584-5p compared to normal epithelial cells.Conclusions: It is possible that miR-584-5p could serve as a promising patent for a therapeutic target and prognostic biomarker for people with HNSC.","PeriodicalId":93961,"journal":{"name":"Current computer-aided drug design","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current computer-aided drug design","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115734099305382240704071258","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: MicroRNA-584-5p (miR-584-5p) plays an important role in certain types of cancer. However, its precise role in head and neck squamous cell carcinoma (HNSC) remains unknown.

Objective: Our aim was to investigate how miR-584-5p influences HNSC.

Methods: The Cancer Genome Atlas (TCGA) provided samples for the study. We use statistical methods to evaluate the diagnostic value, the prognostic value, and the correlation with the clinical features of miR-584-5p. We analyze the target genes and the regulatory network of miR- 584-5p. Quantitative reverse transcriptase PCR (qRT-PCR) confirmed the expression of miR- 584-5p in HNSC cell lines.

Results: MiR-584-5p expression of miR-584-5p varied significantly among different types of cancer. A notable correlation was observed between elevated miR-584-5p expression and gender (p < 0.001) and histological grade (p < 0.001). Furthermore, high levels of miR-584-5p were found to be associated with a decrease in overall survival (HR: 1.44; 95% CI: 1.10-1.88; p = 0.007), progression-free survival (HR: 1.35; 95% CI: 1.02-1.79; p = 0.035) and disease-specific survival (HR: 1.54; 95% CI: 1.09-2.18; p = 0.016) in the context of HNSC. miR-584-5p demonstrated independent prognostic significance in HNSC and potentially contributes to disease progression through multiple pathways, such as dilated cardiomyopathy and hypertrophic cardiomyopathy. In particular, HNSC cell lines exhibited a substantial upregulation of miR-584-5p compared to normal epithelial cells.

Conclusions: It is possible that miR-584-5p could serve as a promising patent for a therapeutic target and prognostic biomarker for people with HNSC.

查看原文本刊更多论文

miR-584-5p 是头颈部鳞状细胞癌潜在的新预后生物标记物

背景：微RNA-584-5p（miR-584-5p）在某些类型的癌症中发挥着重要作用。然而，它在头颈部鳞状细胞癌（HNSC）中的确切作用仍然未知：我们的目的是研究 miR-584-5p 如何影响 HNSC：癌症基因组图谱（TCGA）为本研究提供了样本。我们使用统计方法评估 miR-584-5p 的诊断价值、预后价值以及与临床特征的相关性。我们分析了 miR- 584-5p 的靶基因和调控网络。定量逆转录酶 PCR（qRT-PCR）证实了 miR- 584-5p 在 HNSC 细胞系中的表达：结果：miR- 584-5p 的表达在不同类型的癌症中差异显著。miR-584-5p表达的升高与性别（p < 0.001）和组织学分级（p < 0.001）之间存在明显的相关性。此外，研究发现，高水平的 miR-584-5p 与总生存期（HR：1.44；95% CI：1.10-1.88；p = 0.007）、无进展生存期（HR：1.35；95% CI：1.02-1.79；p = 0.035）和疾病特异性生存期（HR：1.54；95% CI：1.miR-584-5p在HNSC中显示出独立的预后意义，并可能通过多种途径（如扩张型心肌病和肥厚型心肌病）导致疾病进展。特别是，与正常上皮细胞相比，HNSC 细胞系表现出 miR-584-5p 的大量上调：结论：miR-584-5p有可能成为HNSC患者的治疗靶点和预后生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current computer-aided drug design

自引率

0.00%

发文量